UBM Medica Corporate Officers

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.